Table 3.

Summary of clinical outcome of all patients who received and tolerated Ikervis treatment, categorised into five indications (total n=387 patients)

Clinical outcome	DED Total n=285; n (%)	AED Total n=31; n (%)	OMMP/SJS Total n=27; n (%)	Post-graft Total n=14; n (%)	Others Total n=30; n (%)	P value*
Resolved/stable	264 (92.6)	20 (64.5)	25 (92.6)	7 (50.0)	27 (90.0)	<0.001
Active	21 (7.4)	11 (35.5)	2 (7.4)	7 (50.0)	3 (10.0)

*Comparison was made among the five indications.

AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic keratoconjunctivitis; DED, dry eye disease; OMMP, ocular mucous membrane pemphigoid; SJS, Steven-Johnson syndrome.